Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Dysregulation of the complement system is linked to the pathogenesis of a variety of hematological disorders. Eculizumab, an anti-complement C5 monoclonal antibody, is the current standard of care for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). However, because of high levels of C5 in plasma, eculizumab has to be administered biweekly by intravenous infusion. By applying recycling technology through pH-dependent binding to C5, we generated a novel humanized antibody against C5, SKY59, which has long-lasting neutralization of C5. In cynomolgus monkeys, SKY59 suppressed C5 function and complement activity for a significantly longer duration compared to a conventional antibody. Furthermore, epitope mapping by X-ray crystal structure analysis showed that a histidine cluster located on C5 is crucial for the pH-dependent interaction with SKY59. This indicates that the recycling effect of SKY59 is driven by a novel mechanism of interaction with its antigen and is distinct from other known pH-dependent antibodies. Finally, SKY59 showed neutralizing effect on C5 variant p.Arg885His, while eculizumab does not inhibit complement activity in patients carrying this mutation. Collectively, these results suggest that SKY59 is a promising new anti-C5 agent for patients with PNH and other complement-mediated disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00262 · Cited by 1,620
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Complement and Its Receptors: New Insights into Human Disease
Holers, V. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120154 · Cited by 430
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans
Ward, E. S. (2003) · International Immunology · doi:10.1093/intimm/dxg018 · Cited by 216
Cited by
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
The renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
Grevys, A., Frick, R., Mester, S., Flem-Karlsen, K., Nilsen, J., Foss, S., Sand, K. M. K., Emrich, T., Fischer, J. A. A., Greiff, V., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103746 · Cited by 51
“Furthermore, antibodies typically bind one or two soluble antigens, which may prolong their persistence, but it may also increase clearance and result in lower effective antibody doses (Chaparro-Riggers et al., 2012; Fukuzawa et al., 2017).”
Tulika, T., Pedersen, R. W., Rimbault, C., Ahmadi, S., Rivera‐de‐Torre, E., Fernández‐Quintero, M. L., Loeffler, J. R., Bohn, M., Ljungars, A., Ledsgaard, L., et al. (2023) · Protein Science · doi:10.1002/pro.4821 · Cited by 11
Metadata
- Authors
- Fukuzawa, T., Sampei, Z., Haraya, K., Ruike, Y., Shida-Kawazoe, M., Shimizu, Y., Gan, S. W., Irie, M., Tsuboi, Y., Tai, H., Sakiyama, T., Sakamoto, A., Ishii, S., Maeda, A., Iwayanagi, Y., Shibahara, N., Shibuya, M., Nakamura, G., Nambu, T., Hayasaka, A., Mimoto, F., Okura, Y., Hori, Y., Habu, K., Wada, M., Miura, T., Tachibana, T., Honda, K., Tsunoda, H., Kitazawa, T., Kawabe, Y., Igawa, T., Hattori, K., & Nezu, J.
- Venue
- Scientific Reports
- Published
- 2017-04-24
- Volume
- 7
- Issue
- 1
- Pages
- 1080-1080
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2606230253
- Cited by
- 107
- References
- 5
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. https://app.cochat.ai/papers/10.1038/s41598-017-01087-7
- The paper
- Fukuzawa, T., Sampei, Z., Haraya, K., Ruike, Y., Shida-Kawazoe, M., Shimizu, Y., Gan, S. W., Irie, M., Tsuboi, Y., Tai, H., Sakiyama, T., Sakamoto, A., Ishii, S., Maeda, A., Iwayanagi, Y., Shibahara, N., Shibuya, M., Nakamura, G., Nambu, T., . . . Nezu, J. (2017). Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Scientific Reports. https://doi.org/10.1038/s41598-017-01087-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.